Gedea Biotech announces the start of the clinical study VVC2025—first patients enrolled
PRESS RELEASE Gedea Biotech today announced the start of the clinical study VVC2025, following approval from the Swedish Medical Products Agency (Läkemedelsverket). The randomized and controlled study evaluates Gedea’s product pHyph for the relief of signs and symptoms of vulvovaginal candidiasis…
Gedea Biotech strengthens IP portfolio with new European patent for treating infections with GDL
PRESS RELEASE Gedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s intellectual property protection for pHyph in Europe, until 2038. The patent covers the use of glucono delta-lactone (GDL) for the treatment of bacterial vaginosis…
Gedea Biotech strengthens IP portfolio with new US patent for vaginal formulation
PRESS RELEASE Gedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no. 12,496,288). The patent marks an important step for Gedea Biotech in protecting the product on the US market and is expected to be of high strategic value for future…
Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phase
Gedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The Board of Directors has appointed Julie Waras Brogren as the new Chief Executive Officer. Julie has more than 20 years of experience from the…
Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolled
PRESS RELEASE Lund, Sweden, January 22, 2026 Gedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical Products Agency (Läkemedelsverket) for the treatment of bacterial vaginosis. In addition to fulfilling post-approval requirements, the…
Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase
PRESS RELEASE Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today announced the appointment of three new members to its Board of Directors: Paan Hermansson, Berit Lindholm, and Caroline Mofors. “- We are very fortunate to bring strong…
New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journey
At the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a collaboration between Gedea Biotech and Karolinska Institutet (KI). Her research explores one of the
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
Lund, Sweden – September 2, 2025 – Gedea Biotech, an innovative Swedish life science company, today announced that its lead product pHyph has received CE-marking under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis (BV). pHyph is an antibiotic-free vaginal tablet…
PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Lund, Sweden, March 27, 2025 Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application covering the active ingredient in the company’s first product, pHyph, to prevent preterm birth (premature delivery) in pregnant women…
Gedea Biotech Reports Significant Results in Study for the Treatment of Bacterial Vaginosis
PRESS RELEASE Lund, Sweden, March 12, 2025 Gedea Biotech has completed a clinical study, the NEFERTITI-2 study, for the treatment of bacterial vaginosis, showing significantly better treatment outcomes with the company's vaginal tablet pHyph compared to the control group. This result forms the…